Evidence map›Paper›PMID 39082930›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer.

Sean-Luc Shanahan, Nikesh Kunder, Charles Inaku, Natalie B Hagan, Grace Gibbons, Nicolas Mathey-Andrews, Gayathri Anandappa, Shawn Soares, Kristen E Pauken, Tyler Jacks and 1 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sean-Luc ShanahanDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0002-8254-0945
Nikesh KunderDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8456-7703
Charles InakuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0003-0597-6168
Natalie B HaganDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0000-6081-4231
Grace GibbonsDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.
Nicolas Mathey-AndrewsDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.
Gayathri AnandappaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Shawn SoaresDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0001-5433-7037
Kristen E PaukenDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4309-7880
Tyler JacksDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0001-5785-8911
Jason M SchenkelDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Kristin A Knouse · 1985 to 2026
$93.9M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
Studying factors controlling cancer progression and immune recognition in mouse modelsR35CA274464 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TYLER E. JACKS · 2022 to 2026
$4.6M
Oncopathology Training ProgramT32CA251062 · NCI · DANA-FARBER CANCER INST · PI JON C. ASTER, KATHLEEN H BURNS · 2020 to 2026
$2.4M
The ontogeny and function of CD8 T cells in lung cancerK08CA256044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SCHENKEL, JASON M. · 2021 to 2025
$1.1M
Cancer Prevention and Research Institute of Texas (CPRIT) RR220086HHS | National Institutes of Health (NIH) K08-CA256044HHS | National Institutes of Health (NIH) P30-CA14051HHS | National Institutes of Health (NIH) T32-CA251062NCI NIH HHS K08 CA256044NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221703NCI NIH HHS R35 CA274464NCI NIH HHS T32 CA251062NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Anticancer immunity is predicated on leukocyte migration into tumors. Once recruited, leukocytes undergo substantial reprogramming to adapt to the tumor microenvironment. A major challenge in the field is distinguishing recently recruited from resident leukocytes in tumors. In this study, we developed an intravascular Ab technique to label circulating mouse leukocytes before they migrate to tissues, providing unprecedented insight into the kinetics of recruitment. This approach unveiled the substantial role of leukocyte migration in tumor progression using a preclinical mouse model of lung adenocarcinoma. Regulatory T cells (Tregs), critical mediators of immunosuppression, were continuously and rapidly recruited into tumors throughout cancer progression. Moreover, leukocyte trafficking depended on the integrins CD11a/CD49d, and CD11a/CD49d blockade led to significant tumor burden reduction in mice. Importantly, preventing circulating Treg recruitment through depletion or sequestration in lymph nodes was sufficient to decrease tumor burden, indicating that Treg migration was crucial for suppressing antitumor immunity. These findings underscore the dynamic nature of the immune compartment within mouse lung tumors and demonstrate the relevance of a temporal map of leukocyte recruitment into tumors, thereby advancing our understanding of leukocyte migration in the context of tumor development.

Indexed as

Cell MovementDisease Models, AnimalLung NeoplasmsT-Lymphocytes, RegulatoryAdenocarcinomaAnimalsCell Line, TumorMiceMice, Inbred C57BLTumor Microenvironment

Identifiers

PMID39082930
PMCPMC11460633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.